Cancer Family
Malignant Soft Tissue Neoplasm
CI-CAN-00000251Explore in graph →
341 active trials9 approved drugs37 evidence items
- NCIt
- C4867
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000251Explore in graph →
Clinical trials
1,396 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (200)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | terminated | Phase 2 | 31 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Feb 13, 2020 | clinicaltrials |
| NCT03913806 | FLuoresence Image Guided Surgery With A VEGF-targeted Tracer in Soft-tissue Sarcomas in Humans Approach With Bevacizumab-IRDye 800CW(FLASH) | completed | Phase 1 / Phase 2 | 16 | University Medical Center GroningenOTHER |
| 1 |
| Jan 28, 2020 |
| clinicaltrials |
| NCT04239443 | Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer | unknown | Phase 2 | 120 | Hunan Cancer HospitalOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT03139487 | A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism(PRIORITY) | unknown | Phase 2 | 176 | Asan Medical CenterOTHER | 1 | Jan 6, 2020 | clinicaltrials |
| NCT01962103 | Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 107 | CelgeneINDUSTRY | 7 | Dec 27, 2019 | clinicaltrials |
| NCT03121833 | Endostar Combined With Chemotherapy for Stage Ⅳ Soft Tissue Sarcoma | completed | Phase 2 | 52 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 26, 2019 | clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT00717522 | Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma | terminated | Phase 2 | 7 | CelgeneINDUSTRY | 1 | Nov 19, 2019 | clinicaltrials |
| NCT00859456 | Sunitinib in Certain Subtypes of Soft Tissue Sarcomas | terminated | Phase 2 | 10 | Columbia UniversityOTHER | 1 | Nov 4, 2019 | clinicaltrials |
| NCT03469804 | Phase II Multicentric Study of Pembrolizumab in Classic or Endemic Kaposi's Sarcoma(KAPKEY) | unknown | Phase 2 | 17 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT04126811 | Apatinib Combined With Chemotherapy in the Treatment of Soft Tissue Sarcoma | unknown | Phase 2 | 120 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 15, 2019 | clinicaltrials |
| NCT00490451 | A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma | completed | Phase 2 | 101 | Eli Lilly and CompanyINDUSTRY | 3 | Sep 18, 2019 | clinicaltrials |
| NCT02849366 | Combination of Cryosurgery and NK Immunotherapy for Recurrent Sarcoma | completed | Phase 1 / Phase 2 | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT03397186 | Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma | withdrawn | Phase 2 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 10, 2019 | clinicaltrials |
| NCT01782313 | A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas | completed | Phase 2 | 58 | Northwestern UniversityOTHER | 1 | Sep 9, 2019 | clinicaltrials |
| NCT01574716 | Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation(SOURCE) | completed | Phase 2 | 209 | MorphotekINDUSTRY | 6 | Aug 21, 2019 | clinicaltrials |
| NCT01168232 | Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer | completed | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2019 | clinicaltrials |
| NCT01220609 | Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2019 | clinicaltrials |
| NCT01247571 | Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2019 | clinicaltrials |
| NCT00025506 | Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00075400 | Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00025220 | Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT00378911 | Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT01637961 | Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT03946943 | Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma | unknown | Phase 2 | 25 | Di WuOTHER | 1 | Jul 10, 2019 | clinicaltrials |
| NCT03815474 | Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma Patients(ALTER-S005) | unknown | Phase 2 | 47 | Liaoning Cancer Hospital & InstituteOTHER | 1 | Jul 9, 2019 | clinicaltrials |
| NCT02575066 | Clinical Study of Concurrent Pazopanib and Radiotherapy for Non-metastatic Sarcoma Patients(PASART-2) | terminated | Phase 2 | 25 | The Netherlands Cancer InstituteOTHER | 2 | Jun 27, 2019 | clinicaltrials |
| NCT02811159 | An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids | terminated | Phase 2 | 20 | Repros Therapeutics Inc.INDUSTRY | 1 | Jun 27, 2019 | clinicaltrials |
| NCT02323646 | Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids | completed | Phase 2 | 42 | Repros Therapeutics Inc.INDUSTRY | 1 | Jun 25, 2019 | clinicaltrials |
| NCT00958334 | Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003 | completed | Phase 2 | 65 | Repros Therapeutics Inc.INDUSTRY | 1 | Jun 18, 2019 | clinicaltrials |
| NCT01752569 | A Study of Selumetinib in Patients With Kaposi's Sarcoma(SCART) | terminated | Phase 1 / Phase 2 | 19 | Sheffield Teaching Hospitals NHS Foundation TrustOTHER | 1 | Feb 20, 2019 | clinicaltrials |
| NCT01337401 | A Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS)(CASPS) | unknown | Phase 2 | 36 | Institute of Cancer Research, United KingdomOTHER | 3 | Jan 24, 2019 | clinicaltrials |
| NCT00114218 | Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer | completed | Phase 2 | 28 | Gynecologic Oncology GroupNETWORK | 1 | Jan 8, 2019 | clinicaltrials |
| NCT03792542 | Anlotinib Hydrochloride For Advanced Soft Tissue Sarcoma Patients Who Do Not Receive Chemotherapy | unknown | Phase 2 | 44 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jan 3, 2019 | clinicaltrials |
| NCT03219671 | Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS) | unknown | Phase 2 | 20 | Alona ZerOTHER | 1 | Dec 26, 2018 | clinicaltrials |
| NCT02255110 | A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma | terminated | Phase 2 | 6 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Dec 14, 2018 | clinicaltrials |
| NCT01614795 | Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2018 | clinicaltrials |
| NCT00464620 | Trial of Dasatinib in Advanced Sarcomas | completed | Phase 2 | 366 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Nov 23, 2018 | clinicaltrials |
| NCT00038207 | Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies | completed | Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00020683 | A Phase II Trial of COL-3 in Patients With HIV Related Kaposi's Sarcoma | terminated | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Oct 18, 2018 | clinicaltrials |
| NCT00918489 | Study on Efficacy and Tolerability of Vorinostat in Patients With Advanced, Metastatic Soft Tissue Sarcoma (STS)(SAHA-I) | completed | Phase 2 | 40 | Heidelberg UniversityOTHER | 1 | Oct 17, 2018 | clinicaltrials |
| NCT02942537 | Study of Volume Reduction of Uterine Fibroids After Embolization or Microwave Treatment(MYOMIC1) | unknown | Phase 2 / Phase 3 | 36 | Karolinska InstitutetOTHER | 1 | Oct 2, 2018 | clinicaltrials |
| NCT01807468 | Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors | unknown | Phase 2 | 12 | Samsung Medical CenterOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT02784015 | Response Based Treatment for Children With Unresectable Localized Soft Tissue Sarcoma | unknown | Phase 2 | 41 | Samsung Medical CenterOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT00070109 | Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors | completed | Phase 2 | 50 | Children's Oncology GroupNETWORK | 2 | Sep 14, 2018 | clinicaltrials |
| NCT00484341 | Phase II Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Soft Tissue Sarcomas. | completed | Phase 2 | 69 | AGC Biologics S.p.A.INDUSTRY | 3 | Aug 29, 2018 | clinicaltrials |
| NCT01154452 | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 1 / Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Aug 15, 2018 | clinicaltrials |
| NCT02011126 | Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors | withdrawn | Phase 2 | 0 | Children's Oncology GroupNETWORK | 0 | Aug 7, 2018 | clinicaltrials |
| NCT00923936 | Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma | completed | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Feb 13, 2020source: clinicaltrials